Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants

Pediatric Infectious Disease Journal

Volumn 15, Issue 2, 1996, Pages 134-139

  Åhman, Heidi ^a   Käyhty, Helena ^a   Tamminen, Pirjo ^b   Vuorela, Arja ^a   Malinoski, Frank ^c   Eskola, Juhani ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Kerava Health Centre   (Finland)

^c Lederle Praxis Biologicals   (United States)

Author keywords

Immunogenicity; Infants; Pneumococcal conjugate vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEVER; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; INFANT; INFECTION CONTROL; NORMAL HUMAN; PRIORITY JOURNAL; SKIN IRRITATION; STREPTOCOCCUS; STREPTOCOCCUS INFECTION;

ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CHI-SQUARE DISTRIBUTION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION SCHEDULE; INFANT; PNEUMOCOCCAL INFECTIONS; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 0030040727     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199602000-00009     Document Type: Article

References (43)

1. World Health Organization. Programme for the control of acute respiratory infections: pneumococcal conjugate vaccines. Report WHO/ARI/94.34. In: WHO meeting, Geneva, Switzerland, 1994.
2. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990;3:171-96.
3. Breiman RF, Butler J, Tenover F, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;23:1831-5.
4. Klein JO. The epidemiology of pneumococcal disease in infants and children. Rev Infect Dis 1981;3:246-56.
5. Douglas RM, Paton JC, Duncan SJ, Hansman DJ. Antibody response to pneumococcal vaccination in children younger than five years of age. J Infect Dis 1983;148:131-7.
6. Leinonen M, Säkkinen A, Kalliokoski R, Luotonen J, Timonen M, Mäkelä PH. Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in preschool age children. Pediatr Infect Dis 1986;5:39-44.
7. Paton JC, Toogood IR, Cockington RA, Hansman D. Antibody responses to pneumococcal vaccine in children aged 5 to 15 years. Am J Dis Child 1986;140:135-8.
8. Mäkela PH, Sibakov M, Herva E, et al. Pneumococcal vaccine and otitis media. Lancet 1980;2:547-51.
9. Riley ID, Alpers M, Gratten H, Lehmann D, Marshall TFDC, Smith D. Pneumococcal vaccine prevents death from acute lower-respiratory-tract infections in Papua New Guinean children. Lancet 1986:877-81.
10. Avery OT, Goebel WF. Chemoimmunological studies on conjugated carbohydrate proteins: II. Immunological specificity synthetic of sugar-protein antigens. J Exp Med 1929;50:533-50.
11. Braley-Mullen H. Antigen requirements for priming of IgG producing memory cells specific for type III pneumococcal polysaccharide. Immunology 1980;40:521-7.
12. Eskola J, Käyhty H, Peltola H, et al. Antibody levels achieved in infants by course of H. influenzae type b polysaccharide/ diphtheria toxoid conjugate vaccine. Lancet 1985;1:1184-6.
13. Ahonkhai V, Lucakcs L, Jonas L, et al. Clinical experience with PedvaxHIB™, a conjugate vaccine of Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer membrane protein. Vaccine 1991;9(Suppl):S38-41.
14. Schneerson R, Robbins JB, Parke JC, et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986;108:519-28.
15. 197 conjugate vaccine in 1- to 6-month-old infants. Pediatrics 1990;85:331-7.
16. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991;324:1767-72.
17. Vadheim CM, Greenberg DP, Partridge S, Jing J, Ward JI, Kaiser-UCLA Study Group. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Pediatrics 1993;92:272-9.
18. Booy R, Hodgson S, Carpenter, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994;344:362-7.
19. Eskola J, Käyhty H, Takala AK, et al. A randomized prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive H.influenzae type b disease. N Engl J Med 1990;323:1381-7.
20. Black S, Shinefield H, Fireman B, et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61 080 children. Pediatr Infect Dis J 1991;10:97-104.
21. Vella P, Marburg S, Staub J, et al. Immunogenicity of conjugate vaccines consisting of pneumococcal capsular polysaccharide type 6B, 14, 19F and 23F and a meningococcal outer membrane protein, complex. Infect Immun 1992;12:4977-83.
22. Keyserling HL, Anderson AL, Martin TJ. Immunogenicity of a tetravalent (types 6B, 14, 19F and 23F) pneumococcal conjugate vaccine in infants. [Abstract]. Presented at the meeting of The Society for Pediatric Research, Washington, DC, May 3 to 6, 1993.
23. Yogev R, Gupta S, Emanuel B, Williams K, Adams J. Safety, tolerability and immunogenicity of tetravalent (6B, 14, 19F and 23F) pneumococcal (Pnc) conjugate vaccine infants given concurrently with routine immunizations. [Abstract]. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 18 to 20, 1993.
24. Keyserling H, Bosley C, Starr S, et al. Immunogenicity of pneumococcal type 14 conjugate vaccine. [Abstract]. Presented at the meeting of The Society for Pediatric Research, Seattle, WA, May 2 to 5, 1994.
25. Giebink GS, Alward CT, Rzepka AA, Daly K, Lieberer CL. Antibody responses to concurrent type 6B monovalent pneumococcal and Haemophilus influenzae type b (Hib) conjugate vaccines in infants [Abstract]. Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994.
26. Koskela M. Serum antibodies to pneumococcal C-polysaccha- ride in children: response to acute pneumococcal otitis media and to vaccination. Pediatr Infect Dis J 1987;6:519-26.
27. 197 conjugate vaccines in healthy US infants. [Abstract]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 18 to 20, 1995.
28. Åhman H, Kåyhty H, Leroy O, Froeschle J, Eskola J. Immunogenicity of tetravalent pneumococcal (Pnc) conjugate vaccines (PncD, PncT) in Finnish infants. Presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 18 to 20, 1995.
29. Käyhty H, Åhman H, Rönnberg PR, Tillikainen R, Eskola J. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995;172:1273-8.
30. Robbins JB, Parke JC Jr, Schneerson R, Whisnant JK. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzas type b capsular polysaccharide antibodies. Pediatr Res 1973;7:101-10.
31. Mäkelä PH, Peltola H, Käyhty H, et al. Polysaccharide vaccines of group A Neisseria meningitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis 1977;139(Suppl):S43-50.
32. Paradiso PR, Hogerman DA, Viceps Madore D, et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 1993;92:827-32.
33. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62.
34. Eskola J, Käyhty H, Gordon LK, et al. Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-pertussis-tetanus and inactivated polio vaccina- tions of childhood. Pediatr Infect Dis J 1988;7:480-4.
35. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992;20:184-9.
36. Granoff DM, Anderson EL, Osterholm MT, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992;121:187-94.
37. Mäkelä PH, Karma P, Sipilä M, Pukander J, Leinonen M. Possibilities of preventing otitis media by vaccination. Scand J Infect Dis Suppl 1983;39:34-8.
38. Steinhoff MC, Edwards K, Keyserling H, et al. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr Infect Dis J 1994;13:368-74.
39. Käyhty H, Peltola H, Eskola J, et al. Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. Pediatrics 84;6:995-9.
40. Peeters C, Tenbergen-Meekes AM, Haagmans B, et al. Pneumococcal conjugate vaccines. Immunol Lett 1991;30:267-74.
41. Santosham M, Reid R, Ambrosino D, et al. Prevention of Haemophilus influenzae type b infections in high risk infants treated with bacterial polysaccharide immuno-globulin. N Engl J Med 1987;317:923-9.
42. Giebink GS, Koskela M, Vella PP, Harris M, Le C. Pneumococcal capsular polysaccharide meningococcal outer membrane protein complex conjugate vaccines: immunogenicity and efficacy in experimental pneumococcal otitis media. J Infect Dis 1993;167:347-55.
43. Alonso De Velasco E, Dekker BAT, Verheul AFM, et al. Antipolysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice. J Infect Dis 1995;172:562-5.